GnRH agonist peptide analog

Goserelin

Goserelin is a synthetic GnRH analog investigated in pituitary responses and communication between cellular pathways. The molecule, acetate salt and preparation used in each publication must remain distinct.

This is a research reference, not a product offered in the Pureza catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.

Mechanism described in the literature

Preclinical literature classifies goserelin as a GnRH agonist. Prostate models also examined a relationship between GnRH signaling and EGFR; this does not make goserelin a universal direct EGFR inhibitor.

Other names in the literature

Goserelin

Responses during and after exposure

A 1988 work compared GnRH analogs, including goserelin according to article indexing, in rat pituitary research. It distinguished LH released during exposure, persistence afterward and tissue reserves, different aspects of the endocrine response.

A mutation as a mechanistic test

In 2002, investigators compared DU-145 cells with two EGFR versions and mouse xenografts. Goserelin acetate limited growth in the model with unmodified receptor, while the altered variant resisted that effect.

What a genetic control adds

The receptor comparison supported a cellular communication pathway in that experiment, more specifically than growth change alone. It does not demonstrate the same response in every GnRH-receptor-bearing cell or identify direct goserelin binding to EGFR.

Questions and answers

Does goserelin act directly on EGFR?

The cited study examined pathway communication in preclinical models; it did not establish direct binding to EGFR.

Why also measure pituitary reserves?

Tissue content and released hormone are different variables, examined separately in the analog comparison.